Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3911 ARTÍCULOS , VIENDO DEL 796 AL 810

Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease

Gallegos S, Pacheco C, Peters C, Opazo CM, Aguayo LG.

Front Neurosci. 2015 Mar 9;9:59. doi: 10.3389/fnins.2015.00059. eCollection 2015.

Correlation Between Structural and Functional Retinal Changes in Parkinson Disease

Kaur M, Saxena R, Singh D, Behari M, Sharma P, Menon V.

J Neuroophthalmol. 2015 Sep;35(3):254-8. doi: 10.1097/WNO.0000000000000240.

Long-term efficacy of biofeedback therapy in patients with dyssynergic defecation: results of a median 44 months follow-up

Lee HJ, Boo SJ, Jung KW, Han S, Seo SY, Koo HS, Yoon IJ, Park SH, Yang DH, Kim KJ, Ye BD, Byeon JS, Yang SK, Kim JH, Myung SJ.

Neurogastroenterol Motil. 2015 Jun;27(6):787-95. doi: 10.1111/nmo.12552. Epub 2015 Mar 25.

Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson's Disease

Sari Y, Khalil A.

CNS Neurol Disord Drug Targets. 2015;14(6):777-85. doi: 10.2174/1871527314666150325235608.

Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson's Disease

Das NR, Sharma SS.

CNS Neurol Disord Drug Targets. 2015;14(8):1024-30. doi: 10.2174/1871527314666150326000018.

Valbenazine granted breakthrough drug status for treating tardive dyskinesia

Müller T.

Expert Opin Investig Drugs. 2015 Jun;24(6):737-42. doi: 10.1517/13543784.2015.1029573. Epub 2015 Mar 25.

International validation of a behavioral scale in Parkinson's disease without dementia

Rieu I, Martinez-Martin P, Pereira B, De Chazeron I, Verhagen Metman L, Jahanshahi M, Ardouin C, Chéreau I, Brefel-Courbon C, Ory-Magne F, Klinger H, Peyrol F, Schupbach M, Dujardin K, Tison F, Houeto JL, Krack P, Durif F.

Mov Disord. 2015 Apr 15;30(5):705-13. doi: 10.1002/mds.26223. Epub 2015 Mar 21.

Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease

Calandrella D, Romito LM, Elia AE, Del Sorbo F, Bagella CF, Falsitta M, Albanese A.

Neurology. 2015 Apr 21;84(16):1669-72. doi: 10.1212/WNL.0000000000001500. Epub 2015 Mar 25.

Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials

Cummings J, Friedman JH, Garibaldi G, Jones M, Macfadden W, Marsh L, Robert PH.

J Geriatr Psychiatry Neurol. 2015 Sep;28(3):159-73. doi: 10.1177/0891988715573534. Epub 2015 Mar 24.

Monoamine reuptake inhibitors in Parkinson's disease

Huot P, Fox SH, Brotchie JM.

Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25.

Levodopa-Induced Nocturnal Stereotypies with Logorrhea in a Patient with Parkinson's Disease

Antonelli F, Santamaria J, Tolosa E.

Mov Disord Clin Pract. 2015 Mar 28;2(3):301-303. doi: 10.1002/mdc3.12150. eCollection 2015 Sep.

A Case of Apraxic Agraphia in a Patient With Progressive Supranuclear Palsy

Sciacca G, Maci T, Mostile G, Capuana ML, Luca A, Raciti L, Sanfilippo C, Le Pira F, Nicoletti A, Zappia M.

Mov Disord Clin Pract. 2015 Mar 30;2(3):308-309. doi: 10.1002/mdc3.12161. eCollection 2015 Sep.

Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease

Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, Salemi JL, Shaw JD, Sullivan KL; Non-Motor Working Group of the Parkinson Study Group (PSG).

Parkinsonism Relat Disord. 2015 May;21(5):514-20. doi: 10.1016/j.parkreldis.2015.02.025. Epub 2015 Mar 6.

Cognitive impairment in Parkinson's disease

Cosgrove J, Alty JE, Jamieson S.

Postgrad Med J. 2015 Apr;91(1074):212-20. doi: 10.1136/postgradmedj-2015-133247. Epub 2015 Mar 26.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias